142 related articles for article (PubMed ID: 33837029)
1. Bacillus Calmette-Guerin (BCG)-induced balanitis following intravesical immunotherapy for urothelial cancer.
Kumar S; Thummala Y; Parmar KM; Chandna A
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33837029
[No Abstract] [Full Text] [Related]
2. Bacillus Calmette-Guerin (BCG) balanitis as a complication of intravesical BCG immunotherapy: a case report.
Erol A; Ozgür S; Tahtali N; Akbay E; Dalva I; Cetin S
Int Urol Nephrol; 1995; 27(3):307-10. PubMed ID: 7591595
[No Abstract] [Full Text] [Related]
3. Granulomas of the penis: a rare complication of intravesical therapy with Bacillus Calmette-Guerin.
Lestre SI; Gameiro CD; João A; Lopes MJ
An Bras Dermatol; 2011; 86(4):759-62. PubMed ID: 21987145
[TBL] [Abstract][Full Text] [Related]
4. [Calmette-Guerin bacillus disseminated infection after intravesical instillation].
Borré S; Brustia D; Rosa F; Brondolo R; Rizzo G; Garavelli PL
Recenti Prog Med; 2002 Apr; 93(4):247-8. PubMed ID: 11989131
[TBL] [Abstract][Full Text] [Related]
5. Small bladder and multiple urethral recurrences after intravesical instillation of bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
Manasia P; Alcaraz A; Cetina A; Alcover J
J Urol; 2001 Feb; 165(2):529-30. PubMed ID: 11176420
[No Abstract] [Full Text] [Related]
6. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy.
Ozbakkaloglu B; Tünger O; Sürücüoglu S; Lekili M; Kandiloglu AR
Int Urol Nephrol; 1999; 31(1):49-53. PubMed ID: 10408303
[TBL] [Abstract][Full Text] [Related]
7. Haemophagocytic syndrome after intravesical bacille Calmette-Guérin instillation.
Misra S; Gupta A; Symes A; Duncan J
Scand J Urol; 2014 Jun; 48(3):328-30. PubMed ID: 24070063
[TBL] [Abstract][Full Text] [Related]
8. Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma.
Cugati S; Gilhotra JS; Lake S; Gordon DL
Clin Exp Ophthalmol; 2014 Jul; 42(5):494-5. PubMed ID: 24372891
[No Abstract] [Full Text] [Related]
9. Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.
Johnson MH; Nepple KG; Peck V; Trinkaus K; Klim A; Sandhu GS; Kibel AS
J Urol; 2013 Apr; 189(4):1268-74. PubMed ID: 23123375
[TBL] [Abstract][Full Text] [Related]
10. [Miliary tuberculosis in a patient treated with BCG intravesical instillation].
Fernández Jiménez-Ortiz H; Gómez Marco JJ; Rojo Zamanillo I; Fernández Fernández E
Actas Urol Esp; 2007; 31(7):783-4. PubMed ID: 17902475
[TBL] [Abstract][Full Text] [Related]
11. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
Aust TR; Massey JA
Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
[TBL] [Abstract][Full Text] [Related]
12. An unexpected complication of bacillus Calmette-Guérin therapy.
Yildiz H; Colin G; Lambert M
Acta Clin Belg; 2014 Aug; 69(4):312. PubMed ID: 24846180
[No Abstract] [Full Text] [Related]
13. [Endovesical immunotherapy: Calmette-Guérin bacillus].
Chopin D; Saint F; Gattegno B
Prog Urol; 2001 Nov; 11(5):1067-115. PubMed ID: 11769075
[No Abstract] [Full Text] [Related]
14. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
15. [Relapsing Reiter's syndrome after Bacillus Calmette-Guérin immunotherapy for bladder carcinoma].
Pego JM; Lamas C; Hernández I; Suso J
Med Clin (Barc); 2003 Sep; 121(9):356-7. PubMed ID: 14499076
[No Abstract] [Full Text] [Related]
16. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
[TBL] [Abstract][Full Text] [Related]
18. Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer.
Kaneko T; Fujita K; Homma Y
Int J Urol; 2006 Mar; 13(3):294-5. PubMed ID: 16643629
[TBL] [Abstract][Full Text] [Related]
19. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
20. Prostatorectal fistula following intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the urinary bladder.
Enatsu N; Ota T; Ochi A
Int J Urol; 2010 Sep; 17(9):822-3. PubMed ID: 20727055
[No Abstract] [Full Text] [Related]
[Next] [New Search]
